Form 4: ClearPoint Neuro Director R. John Fletcher Reports Stock Unit Conversion
SEC Form 4 Filing
Director R. John Fletcher converted 17,153 restricted stock units into common stock of ClearPoint Neuro, Inc.
Summary
- On May 14, 2024, R. John Fletcher, a director of ClearPoint Neuro, Inc., converted 17,153 restricted stock units into common stock.
- The conversion was reported in a Form 4 filing with the SEC.
- Following the transaction, Fletcher directly owns 91,950 shares of ClearPoint Neuro common stock.
- The restricted stock units were granted on May 25, 2023, and vested on the earlier of the first anniversary of the grant date or the day immediately preceding the company's 2024 annual meeting of stockholders.
Sentiment
Score: 5
Explanation: This is a routine disclosure of a stock unit conversion, neither particularly positive nor negative.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.
Stakeholder Impact
- The conversion of restricted stock units into common stock may have a minor dilutive effect on existing shareholders.
Key Dates
| Date | Description |
|---|---|
| 05/25/2023 | Reporting person was granted 17,153 restricted stock units. |
| 05/14/2024 | R. John Fletcher converted 17,153 restricted stock units into common stock. |
| 05/15/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.